Related Experiment Video
Updated: Sep 15, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Novel strategy for overcoming interference from anti-CD47 agents in pretransfusion testing
Hua Wei1, Jie Chen2, Dongxia Ren1
1Department of Transfusion Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
CD47 is an important immune checkpoint in haematopoietic and solid malignancies. However, panreactivity of anti-CD47 agents leads to interference during pretransfusion compatibility testing binding to red blood cells. To address this issue, we created immunomagnetic beads (IMBs) to adsorb anti-CD47 monoclonal antibodies (mAbs): IMB-OVCAR3, coated with lysed protein from the OVCAR3 cell line, which was screened using flow cytometry and immunofluorescence staining, and IMB-CD47, coated with a recombinant CD47 protein. Plasma adsorbed by IMBs was collected for gel column agglutination testing and flow cytometry to verify elimination of anti-CD47 mAb interference. The effects of IMBs on irregular antibody screening and adsorption ability of IMBs over preservation time were also analysed. Following successful preparation, IMBs were shown to adsorb anti-CD47 mAb in plasma and reduce anti-CD47 mAb interference of simulated and clinical samples in 30 s. Moreover, IMBs did not adsorb irregular antibodies. Both IMBs retained their anti-CD47 mAb adsorption capacity for 3 weeks in a preservation solution. IMB-OVCAR3 and IMB-CD47 can serve as novel tools for the efficient removal of CD47 interference during transfusion compatibility testing in transfusion laboratories.
CD47 is an important immune checkpoint in haematopoietic and solid malignancies. However, panreactivity of anti-CD47 agents leads to interference during pretransfusion compatibility testing binding to red blood cells. To address this issue, we created immunomagnetic beads (IMBs) to adsorb anti-CD47 monoclonal antibodies (mAbs): IMB-OVCAR3, coated with lysed protein from the OVCAR3 cell line, which was screened using flow cytometry and immunofluorescence staining, and IMB-CD47, coated with a recombinant CD47 protein. Plasma adsorbed by IMBs was collected for gel column agglutination testing and flow cytometry to verify elimination of anti-CD47 mAb interference. The effects of IMBs on irregular antibody screening and adsorption ability of IMBs over preservation time were also analysed. Following successful preparation, IMBs were shown to adsorb anti-CD47 mAb in plasma and reduce anti-CD47 mAb interference of simulated and clinical samples in 30 s. Moreover, IMBs did not adsorb irregular antibodies. Both IMBs retained their anti-CD47 mAb adsorption capacity for 3 weeks in a preservation solution. IMB-OVCAR3 and IMB-CD47 can serve as novel tools for the efficient removal of CD47 interference during transfusion compatibility testing in transfusion laboratories.
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
11:31Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols
Published on: January 2, 2013
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...